PRESS RELEASE

Q4 2022 — Press release

Q4 2022PDF · 24 pages729 KB
FOR IMMEDIATE RELEASE
• 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable
foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding
COVID-19 Vaccine of 4.6%*
• 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35
increasing by 10.3%*
__________________________________________________________________________________________
• 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial
execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
• 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15
increasing by 3.6%*
__________________________________________________________________________________________
• Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and
adjusted operational EPS of $10.50, reflecting growth of 3.5%*
New Brunswick, N.J. (January 24, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-
quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three
business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief
Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around
the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth,
while also investing strategically to deliver long-term value.”
OVERALL FINANCIAL RESULTS
Q4 Full Year
($ in Millions, except EPS) 2022 2021 % Change 2022 2021 % Change
Reported Sales $23,706 $24,804 (4.4)% $94,943 $93,775 1.3%
Net Earnings $3,520 $4,736 (25.7)% $17,941 $20,878 (14.1)%
EPS (diluted) $1.33 $1.77 (24.9)% $6.73 $7.81 (13.8)%

-- 1 of 24 --

Q4 Full Year
Non-GAAP* ($ in Millions, except EPS) 2022 2021 % Change 2022 2021 % Change
Operational Sales1,2 0.9% 6.1%
Adjusted Operational Sales1,3 0.8% 6.2%
Adjusted Net Earnings1,4 $6,218 $5,678 9.5% $27,038 $26,195 3.2%
Adjusted EPS (diluted)1,4 $2.35 $2.13 10.3% $10.15 $9.80 3.6%
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: values may have been rounded
REGIONAL SALES RESULTS
Q4 % Change
($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $12,516 $12,163 2.9% 2.9 - 2.7
International 11,190 12,641 (11.5) (1.1) (10.4) (1.0)
Worldwide $23,706 $24,804 (4.4)% 0.9 (5.3) 0.8
Full Year % Change
($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $48,580 $47,156 3.0% 3.0 - 3.0
International 46,363 46,619 (0.6)% 9.1 (9.7) 9.3
Worldwide $94,943 $93,775 1.3% 6.1 (4.8) 6.2
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded
SEGMENT SALES RESULTS
Q4 % Change
($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted
Operational1,3
Consumer Health4 $3,767 $3,728 1.0% 6.4 (5.4) 6.4
Pharmaceutical4 13,163 14,217 (7.4) (2.5) (4.9) (2.3)
MedTech 6,776 6,859 (1.2) 4.9 (6.1) 4.4
Worldwide $23,706 $24,804 (4.4)% 0.9 (5.3) 0.8

-- 2 of 24 --

Full Year % Change
($ in Millions) 2022 2021 Reported Operational1,2 Currency Adjusted
Operational1,3
Consumer Health4 $14,953 $15,035 (0.5)% 3.6 (4.1) 3.9
Pharmaceutical4 52,563 51,680 1.7 6.7 (5.0) 6.8
MedTech 27,427 27,060 1.4 6.2 (4.8) 6.1
Worldwide $94,943 $93,775 1.3% 6.1 (4.8) 6.2
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on
operational changes
Note: Values may have been rounded
FULL YEAR 2022 SEGMENT COMMENTARY:
Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and
translational currency.
Consumer Health
Consumer Health worldwide adjusted operational sales increased 3.9%* predominately driven by over-the-
counter (OTC) products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, as well
as upper respiratory products and digestive health products in the international markets. Additionally, Skin
Health/Beauty adjusted operational growth was primarily driven by NEUTROGENA outside the U.S. Growth was
partially offset by Oral Care in the international markets.
Pharmaceutical
Pharmaceutical worldwide adjusted operational sales grew 6.8%*, driven by DARZALEX (daratumumab), a
biologic for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number
of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor
inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment
of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, and INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable
atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by declines
in sales of REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated
inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain
B-cell malignancies, a type of blood or lymph node cancer, and ZYTIGA (abiratone acetate), an oral, once daily

-- 3 of 24 --

medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate
cancer.
MedTech
MedTech worldwide adjusted operational sales grew 6.1%*, driven primarily by electrophysiology products in
Interventional Solutions, contact lenses in Vision, and wound closure products in General Surgery.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other
disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K,
Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review
all other news releases and information available in the Investors section of the company’s
website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and
www.LTLManagementInformation.com.
Regulatory
DePuy Synthes Receives FDA Clearance for TELIGEN System Press
Release
U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody
for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Press
Release
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of
Patients with Relapsed or Refractory Multiple Myeloma
Press
Release
Data
Release
New TREMFYA (guselkumab) Data Shows an Overall Clinical Response Rate of Approximately
80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative
Colitis
Press
Release
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with
Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
Press
Release
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and
Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control
Hypertension
Press
Release
New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With
Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
Press
Release
New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term
Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient
Population
Press
Release
CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying
Stroke-Inducing Blood Clots
Press
Release
Other
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board Press
Release
Johnson & Johnson Completes Acquisition of Abiomed Press
Release

-- 4 of 24 --

FULL-YEAR 2023 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company
is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable
effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's
results computed in accordance with GAAP.
($ in Billions, except EPS) January 2023
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 3.5% – 4.5% / 4.0%
Operational Sales2,5/ Mid-point2,5
Change vs. Prior Year / Mid-point
$96.9B – $97.9B / $97.4B
4.5% – 5.5% / 5.0%
Estimated Reported Sales3,5/ Mid-point3,5
Change vs. Prior Year / Mid-point
$96.9B – $97.9B / $97.4B
4.5% – 5.5% / 5.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point2,4
Change vs. Prior Year / Mid-point
$10.40 – $10.60 / $10.50
2.5% – 4.5% / 3.5%
Adjusted EPS (Diluted)3,4 / Mid-point3,4
Change vs. Prior Year / Mid-point
$10.45 – $10.65 / $10.55
3.0% – 5.0% / 4.0%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2023 = $1.08 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30
a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two
hours after the live webcast in the Investors section of the company's website at events-and-presentations.

-- 5 of 24 --

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage
of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using
our reach and size for good. We strive to improve access and affordability, create healthier communities, and put
a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science
and ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net
earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding
after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not
be considered replacements for, and should be read together with, the most comparable GAAP financial
measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most
directly comparable GAAP financial measures can be found in the accompanying financial schedules of the
earnings release and the Investors section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website
at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline
of selected compounds in late stage development and a copy of today’s earnings call presentation can also be
found in the Investors section of the company's website at quarterly results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act
of 1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The
reader is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency
exchange rate fluctuations; competition, including technological advances, new products and patents attained by
competitors; challenges inherent in new product research and development, including uncertainty of clinical success
and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges

-- 6 of 24 --

to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the
impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply
chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse
litigation or government action, including related to product liability claims; changes to applicable laws and
regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes
in behavior and spending patterns of purchasers of health care products and services; financial instability of
international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by
government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of
the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate
the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New
Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the
impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and
restrictive measures implemented in response, material delays and cancellations of medical procedures, supply
chain disruptions and other impacts to the business, or on the company’s ability to execute business continuity
plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2,
2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A.
Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the
date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of
new information or future events or developments.
Press Contacts: Investor Contacts:
Tesia Williams Jessica Moore
media-relations@its.jnj.com RA-JJCUS-InvestorRel@ITS.JNJ.com

-- 7 of 24 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
segment of business
Consumer Health (1)
U.S. 1,696	$ 1,529 10.9 % 10.9 - 6,599	$ 6,516 1.3 % 1.3 -
International 2,071 2,199 (5.8) 3.2 (9.0) 8,354 8,519 (1.9) 5.3 (7.2)
3,767 3,728 1.0 6.4 (5.4) 14,953 15,035 (0.5) 3.6 (4.1)
Pharmaceutical (1)
U.S. 7,375 7,418 (0.6) (0.6) - 28,604 27,954 2.3 2.3 -
International 5,788 6,799 (14.9) (4.5) (10.4) 23,959 23,726 1.0 11.9 (10.9)
13,163 14,217 (7.4) (2.5) (4.9) 52,563 51,680 1.7 6.7 (5.0)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
U.S. 7,375 7,205 2.4 2.4 - 28,484 27,320 4.3 4.3 -
International 5,099 5,394 (5.5) 6.0 (11.5) 21,900 21,975 (0.3) 10.3 (10.6)
12,474 12,599 (1.0) 3.9 (4.9) 50,384 49,295 2.2 6.9 (4.7)
MedTech (2)
U.S. 3,445 3,216 7.1 7.1 - 13,377 12,686 5.4 5.4 -
International 3,331 3,643 (8.6) 2.9 (11.5) 14,050 14,374 (2.3) 6.9 (9.2)
6,776 6,859 (1.2) 4.9 (6.1) 27,427 27,060 1.4 6.2 (4.8)
U.S. 12,516 12,163 2.9 2.9 - 48,580 47,156 3.0 3.0 -
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706 24,804 (4.4) 0.9 (5.3) 94,943 93,775 1.3 6.1 (4.8)
U.S. 12,516 11,950 4.7 4.7 - 48,460 46,522 4.2 4.2 -
International 10,501 11,236 (6.5) 4.4 (10.9) 44,304 44,868 (1.3) 8.2 (9.5)
Worldwide excluding COVID-19 Vaccine (3)
23,017	$ 23,186 (0.7) % 4.6 (5.3) 92,764	$ 91,390 1.5 % 6.2 (4.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
FOURTH QUARTER TWELVE MONTHS
Percent Change
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule.

-- 8 of 24 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,516	$ 12,163 2.9 % 2.9 - 48,580	$ 47,156 3.0 % 3.0 -
Europe 5,816 6,925 (16.0) (6.3) (9.7) 23,449 23,594 (0.6) 11.0 (11.6)
Western Hemisphere excluding U.S. 1,545 1,459 5.9 11.8 (5.9) 6,125 5,750 6.5 10.2 (3.7)
Asia-Pacific, Africa 3,829 4,257 (10.0) 3.1 (13.1) 16,789 17,275 (2.8) 6.2 (9.0)
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706	$ 24,804 (4.4) % 0.9 (5.3) 94,943	$ 93,775 1.3 % 6.1 (4.8)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 9 of 24 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 23,706	$ 100.0 24,804	$ 100.0 (4.4)
Cost of products sold 7,765 32.8 7,955 32.1 (2.4)
Gross Profit 15,941 67.2 16,849 67.9 (5.4)
Selling, marketing and administrative expenses 6,512 27.4 7,154 28.9 (9.0)
Research and development expense 3,841 16.2 4,720 19.0 (18.6)
In-process research and development 173 0.7 0 0.0
Interest (income) expense, net (77) (0.3) 47 0.2
Other (income) expense, net 1,207 5.1 9 0.0
Restructuring 84 0.4 83 0.3
Earnings before provision for taxes on income 4,201 17.7 4,836 19.5 (13.1)
Provision for taxes on income 681 2.9 100 0.4 581.0
Net earnings 3,520	$ 14.8 4,736	$ 19.1 (25.7)
Net earnings per share (Diluted) 1.33	$ 1.77	$ (24.9)
Average shares outstanding (Diluted) 2,650.1 2,670.2
Effective tax rate 16.2 % 2.1 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,418	$ 31.3 6,339	$ 25.6 17.0
Net earnings 6,218	$ 26.2 5,678	$ 22.9 9.5
Net earnings per share (Diluted) 2.35	$ 2.13	$ 10.3
Effective tax rate 16.2 % 10.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2022 2021

-- 10 of 24 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 94,943	$ 100.0 93,775	$ 100.0 1.3
Cost of products sold 31,089 32.7 29,855 31.8 4.1
Gross Profit 63,854 67.3 63,920 68.2 (0.1)
Selling, marketing and administrative expenses 24,765 26.1 24,659 26.3 0.4
Research and development expense 14,603 15.4 14,714 15.7 (0.8)
In-process research and development 783 0.8 900 1.0
Interest (income) expense, net (214) (0.2) 130 0.1
Other (income) expense, net 1,871 2.0 489 0.5
Restructuring 321 0.3 252 0.3
Earnings before provision for taxes on income 21,725 22.9 22,776 24.3 (4.6)
Provision for taxes on income 3,784 4.0 1,898 2.0 99.4
Net earnings 17,941	$ 18.9 20,878	$ 22.3 (14.1)
Net earnings per share (Diluted) 6.73	$ 7.81	$ (13.8)
Average shares outstanding (Diluted) 2,663.9 2,674.0
Effective tax rate 17.4 % 8.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 31,880	$ 33.6 30,464	$ 32.5 4.6
Net earnings 27,038	$ 28.5 26,195	$ 27.9 3.2
Net earnings per share (Diluted) 10.15	$ 9.80	$ 3.6
Effective tax rate 15.2 % 14.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2022 2021

-- 11 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2022 2021 2022 2021
Net Earnings, after tax- as reported $3,520 $4,736 $17,941 $20,878
Pre-tax Adjustments
Intangible Asset Amortization expense 1,061 1,121 4,305 4,697
Litigation related 262 274 866 2,328
IPR&D 173 - 783 900
Restructuring related 140 140 463 473
Acquisition, integration and divestiture related ¹ 196 26 196 (478)
(Gains)/losses on securities 6 (198) 690 (533)
Medical Device Regulation 2 88 73 296 234
COVID-19 Vaccine related costs 3 821 - 1,474 -
Consumer Health separation costs 470 67 1,089 67
Other - - (7) -
Tax Adjustments
Tax impact on special item adjustments 4 (507) (184) (1,592) (1,281)
Consumer Health separation tax related costs 35 - 494 -
Tax legislation and other tax related (47) (377) 40 (1,090)
Adjusted Net Earnings, after tax $6,218 $5,678 $27,038 $26,195
Average shares outstanding (Diluted) 2,650.1 2,670.2 2,663.9 2,674.0
Adjusted net earnings per share (Diluted) $2.35 $2.13 $10.15 $9.80
Operational adjusted net earnings per share (Diluted) $2.46 $10.70
Notes:
1
2
3
4
Fourth Quarter Twelve Months Ended
Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition. Acquisition, integration and divestiture related for 2021
primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing
European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May
2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded
only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing
performance which is expected to be completed during 2024.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted
earnings.
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses,
associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual
requirements.

-- 12 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported 1.0% (7.4)% (1.2)% (4.4)%
U.S. 10.9% (0.6)% 7.1% 2.9%
International (5.8)% (14.9)% (8.6)% (11.5)%
WW Currency (5.4) (4.9) (6.1) (5.3)
U.S. - - - -
International (9.0) (10.4) (11.5) (10.4)
WW Operational 6.4% (2.5)% 4.9% 0.9%
U.S. 10.9% (0.6)% 7.1% 2.9%
International 3.2% (4.5)% 2.9% (1.1)%
Interventional Solutions
Abiomed (0.5) (0.1)
U.S. (1.0) (0.3)
International 0.0 0.0
All Other Acquisitions and Divestitures 0.0 0.2 0.0 0.1
U.S. 0.1 0.2 (0.2) 0.1
International 0.0 0.1 0.1 0.1
WW Adjusted Operational 6.4% (2.3)% 4.4% 0.8%
U.S. 11.0% (0.4)% 5.9% 2.7%
International 3.2% (4.4)% 3.0% (1.0)%
Adjusted Operational Sales Growth
FOURTH QUARTER 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (0.5)% 1.7% 1.4% 1.3%
U.S. 1.3% 2.3% 5.4% 3.0%
International (1.9)% 1.0% (2.3)% (0.6)%
WW Currency (4.1) (5.0) (4.8) (4.8)
U.S. - - - -
International (7.2) (10.9) (9.2) (9.7)
WW Operational 3.6% 6.7% 6.2% 6.1%
U.S. 1.3% 2.3% 5.4% 3.0%
International 5.3% 11.9% 6.9% 9.1%
All Other Acquisitions and Divestitures 0.3 0.1 (0.1) 0.1
U.S. 0.2 0.2 (0.4) 0.0
International 0.5 0.1 0.1 0.2
WW Adjusted Operational 3.9% 6.8% 6.1% 6.2%
U.S. 1.5% 2.5% 5.0% 3.0%
International 5.8% 12.0% 7.0% 9.3%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
Segments

-- 14 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 754	$ 633 18.9% 18.9% - 2,782	$ 2,594 7.3% 7.3% -
Intl 815 811 0.6% 9.6% -9.0% 3,249 3,034 7.1% 14.5% -7.4%
WW 1,569 1,444 8.6% 13.7% -5.1% 6,031 5,627 7.2% 11.2% -4.0%
SKIN HEALTH / BEAUTY
US 573 538 6.5% 6.5% - 2,337 2,400 -2.6% -2.6% -
Intl 515 546 -5.6% 4.4% -10.0% 2,015 2,141 -5.9% 2.2% -8.1%
WW 1,088 1,084 0.4% 5.4% -5.0% 4,352 4,541 -4.2% -0.4% -3.8%
ORAL CARE
US 164 159 3.3% 3.3% - 635 637 -0.3% -0.3% -
Intl 207 246 -16.0% -8.1% -7.9% 871 1,008 -13.6% -7.4% -6.2%
WW 370 405 -8.4% -3.7% -4.7% 1,505 1,645 -8.5% -4.7% -3.8%
BABY CARE
US 93 90 3.4% 3.4% - 357 378 -5.5% -5.5% -
Intl 264 309 -14.6% -7.4% -7.2% 1,104 1,188 -7.1% -1.4% -5.7%
WW 356 399 -10.6% -5.0% -5.6% 1,461 1,566 -6.7% -2.4% -4.3%
WOMEN'S HEALTH
US 4 4 15.6% 15.6% - 13 13 1.7% 1.7% -
Intl 217 230 -5.7% 4.4% -10.1% 891 905 -1.5% 7.1% -8.6%
WW 220 233 -5.5% 4.6% -10.1% 904 917 -1.5% 7.0% -8.5%
WOUND CARE / OTHER
US 109 106 3.3% 3.3% - 475 495 -4.0% -4.0% -
Intl 54 57 -7.5% 2.9% -10.4% 224 243 -8.0% -3.4% -4.6%
WW 163 164 -0.5% 3.1% -3.6% 700 739 -5.3% -3.8% -1.5%
TOTAL CONSUMER HEALTH
US 1,696 1,529 10.9% 10.9% - 6,599 6,516 1.3% 1.3% -
Intl 2,071 2,199 -5.8% 3.2% -9.0% 8,354 8,519 -1.9% 5.3% -7.2%
WW 3,767	$ 3,728 1.0% 6.4% -5.4% 14,953	$ 15,035 -0.5% 3.6% -4.1%
See footnotes at end of schedule
% Change % Change

-- 15 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
IMMUNOLOGY
US 2,805	$ 2,912 -3.6% -3.6% - 11,036	$ 10,843 1.8% 1.8% -
Intl 1,312 1,443 -9.1% 2.1% -11.2% 5,899 5,907 -0.1% 10.3% -10.4%
WW 4,118 4,355 -5.4% -1.8% -3.6% 16,935 16,750 1.1% 4.8% -3.7%
REMICADE
US 318 511 -37.7% -37.7% - 1,417 2,019 -29.8% -29.8% -
US Exports (4) 41 39 5.1% 5.1% - 204 236 -13.6% -13.6% -
Intl 116 214 -45.9% -41.3% -4.6% 722 935 -22.8% -18.7% -4.1%
WW 475 764 -37.8% -36.5% -1.3% 2,343 3,190 -26.6% -25.3% -1.3%
SIMPONI / SIMPONI ARIA
US 280 287 -2.2% -2.2% - 1,166 1,127 3.5% 3.5% -
Intl 220 271 -18.6% -7.4% -11.2% 1,017 1,148 -11.4% -1.4% -10.0%
WW 501 559 -10.2% -4.7% -5.5% 2,184 2,276 -4.0% 1.0% -5.0%
STELARA
US 1,621 1,542 5.2% 5.2% - 6,388 5,938 7.6% 7.6% -
Intl 764 792 -3.5% 8.1% -11.6% 3,335 3,196 4.4% 15.7% -11.3%
WW 2,386 2,334 2.3% 6.2% -3.9% 9,723 9,134 6.5% 10.4% -3.9%
TREMFYA
US 541 528 2.5% 2.5% - 1,844 1,503 22.7% 22.7% -
Intl 211 165 27.5% 44.5% -17.0% 824 624 32.0% 47.8% -15.8%
WW 752 693 8.5% 12.5% -4.0% 2,668 2,127 25.4% 30.1% -4.7%
OTHER IMMUNOLOGY
US 3 6 -53.5% -53.5% - 17 21 -18.4% -18.4% -
Intl 0 0 * * * 0 3 * * *
WW 3 6 -53.3% -53.3% 0.0% 17 24 -28.2% -28.2% 0.0%
INFECTIOUS DISEASES
US 414 614 -32.6% -32.6% - 1,680 2,249 -25.3% -25.3% -
Intl 1,127 1,818 -38.0% -31.0% -7.0% 3,769 3,576 5.4% 17.3% -11.9%
WW 1,540 2,431 -36.6% -31.4% -5.2% 5,449 5,825 -6.5% 0.8% -7.3%
COVID-19 VACCINE
US 0 213 * * - 120 634 -81.1% -81.1% -
Intl 689 1,405 -50.9% -45.0% -5.9% 2,059 1,751 17.6% 32.1% -14.5%
WW 689 1,619 -57.4% -52.2% -5.2% 2,179 2,385 -8.6% 2.0% -10.6%
EDURANT / rilpivirine
US 9 10 1.2% 1.2% - 36 41 -10.8% -10.8% -
Intl 281 220 27.6% 39.2% -11.6% 972 953 2.0% 12.7% -10.7%
WW 290 230 26.5% 37.6% -11.1% 1,008 994 1.5% 11.8% -10.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 398 380 4.7% 4.7% - 1,494 1,508 -1.0% -1.0% -
Intl 95 135 -29.5% -20.5% -9.0% 449 575 -21.9% -13.4% -8.5%
WW 493 515 -4.3% -1.9% -2.4% 1,943 2,083 -6.7% -4.4% -2.3%
OTHER INFECTIOUS DISEASES
US 6 11 -47.1% -47.1% - 30 66 -55.5% -55.5% -
Intl 61 57 7.3% 18.0% -10.7% 289 297 -2.6% 3.6% -6.2%
WW 67 68 -1.6% 7.4% -9.0% 318 363 -12.3% -7.2% -5.1%
% Change % Change

-- 16 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
NEUROSCIENCE
US 912 899 1.4% 1.4% - 3,570 3,347 6.7% 6.7% -
Intl 825 890 -7.2% 3.3% -10.5% 3,323 3,641 -8.7% 0.4% -9.1%
WW 1,737 1,789 -2.8% 2.4% -5.2% 6,893 6,988 -1.4% 3.4% -4.8%
CONCERTA / Methylphenidate
US 37 55 -34.3% -34.3% - 151 172 -12.5% -12.5% -
Intl 131 123 6.5% 20.3% -13.8% 493 495 -0.4% 9.9% -10.3%
WW 168 178 -6.2% 3.4% -9.6% 644 667 -3.5% 4.1% -7.6%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 678 668 1.8% 1.8% - 2,714 2,550 6.5% 6.5% -
Intl 329 361 -8.8% 2.7% -11.5% 1,426 1,472 -3.1% 7.8% -10.9%
WW 1,008 1,029 -2.0% 2.1% -4.1% 4,140 4,022 3.0% 6.9% -3.9%
RISPERDAL CONSTA
US 62 77 -19.4% -19.4% - 257 287 -10.4% -10.4% -
Intl 50 63 -21.5% -9.7% -11.8% 228 305 -25.3% -15.5% -9.8%
WW 112 140 -20.4% -15.0% -5.4% 485 592 -18.1% -13.0% -5.1%
OTHER NEUROSCIENCE
US 134 99 35.5% 35.5% - 447 338 32.4% 32.4% -
Intl 315 342 -7.7% 0.3% -8.0% 1,176 1,368 -14.1% -7.5% -6.6%
WW 449 441 2.0% 8.2% -6.2% 1,623 1,706 -4.9% 0.4% -5.3%
ONCOLOGY
US 1,857 1,594 16.5% 16.5% - 6,930 5,958 16.3% 16.3% -
Intl 2,069 2,184 -5.3% 6.8% -12.1% 9,052 8,590 5.4% 17.3% -11.9%
WW 3,927 3,778 3.9% 10.9% -7.0% 15,983 14,548 9.9% 16.9% -7.0%
DARZALEX
US 1,139 867 31.4% 31.4% - 4,210 3,169 32.8% 32.8% -
Intl 944 778 21.3% 36.7% -15.4% 3,767 2,854 32.0% 47.0% -15.0%
WW 2,083 1,645 26.6% 33.9% -7.3% 7,977 6,023 32.4% 39.5% -7.1%
ERLEADA
US 275 235 17.2% 17.2% - 968 813 19.2% 19.2% -
Intl 266 149 78.0% 97.8% -19.8% 913 478 * * *
WW 541 384 40.9% 48.6% -7.7% 1,881 1,291 45.7% 53.0% -7.3%
IMBRUVICA
US 318 436 -27.0% -27.0% - 1,390 1,747 -20.4% -20.4% -
Intl 547 626 -12.5% -2.0% -10.5% 2,394 2,622 -8.7% 1.0% -9.7%
WW 866 1,062 -18.5% -12.3% -6.2% 3,784 4,369 -13.4% -7.6% -5.8%
ZYTIGA / abiraterone acetate
US 20 23 -14.3% -14.3% - 74 119 -37.8% -37.8% -
Intl 250 525 -52.4% -44.8% -7.6% 1,696 2,178 -22.1% -12.3% -9.8%
WW 270 548 -50.8% -43.6% -7.2% 1,770 2,297 -22.9% -13.6% -9.3%
OTHER ONCOLOGY
US 106 34 * * - 289 110 * * -
Intl 63 106 -41.1% -33.1% -8.0% 283 458 -38.3% -31.6% -6.7%
WW 168 140 20.6% 26.7% -6.1% 571 568 0.6% 6.0% -5.4%
% Change % Change

-- 17 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 610 587 3.9% 3.9% - 2,346 2,365 -0.8% -0.8% -
Intl 261 264 -1.3% 13.5% -14.8% 1,071 1,085 -1.3% 11.2% -12.5%
WW 870 851 2.3% 6.9% -4.6% 3,417 3,450 -1.0% 3.0% -4.0%
OPSUMIT
US 305 286 7.0% 7.0% - 1,132 1,147 -1.3% -1.3% -
Intl 156 162 -3.7% 11.0% -14.7% 651 672 -3.2% 9.3% -12.5%
WW 461 448 3.1% 8.4% -5.3% 1,783 1,819 -2.0% 2.6% -4.6%
UPTRAVI
US 280 264 6.3% 6.3% - 1,104 1,056 4.5% 4.5% -
Intl 56 46 20.4% 33.3% -12.9% 218 181 20.4% 32.4% -12.0%
WW 336 310 8.4% 10.3% -1.9% 1,322 1,237 6.9% 8.6% -1.7%
OTHER PULMONARY HYPERTENSION
US 24 38 -35.5% -35.5% - 110 163 -32.3% -32.3% -
Intl 48 56 -12.2% 4.4% -16.6% 202 232 -12.8% 0.3% -13.1%
WW 73 94 -21.7% -11.8% -9.9% 313 395 -20.8% -13.1% -7.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 776 813 -4.4% -4.4% - 3,042 3,192 -4.7% -4.7% -
Intl 194 200 -3.4% 5.7% -9.1% 845 927 -8.9% -1.7% -7.2%
WW 971 1,013 -4.2% -2.4% -1.8% 3,887 4,119 -5.6% -4.0% -1.6%
XARELTO
US 667 644 3.4% 3.4% - 2,473 2,438 1.4% 1.4% -
Intl - - - - - - - - - -
WW 667 644 3.4% 3.4% - 2,473 2,438 1.4% 1.4% -
INVOKANA / INVOKAMET
US 29 59 -51.3% -51.3% - 193 308 -37.4% -37.4% -
Intl 62 60 2.3% 11.2% -8.9% 255 254 0.1% 7.3% -7.2%
WW 91 120 -24.1% -19.6% -4.5% 448 563 -20.4% -17.2% -3.2%
OTHER
US 81 110 -25.7% -25.7% - 376 446 -15.5% -15.5% -
Intl 132 140 -5.9% 3.3% -9.2% 590 673 -12.3% -5.1% -7.2%
WW 213 250 -14.6% -9.4% -5.2% 966 1,119 -13.6% -9.3% -4.3%
TOTAL PHARMACEUTICAL
US 7,375 7,418 -0.6% -0.6% - 28,604 27,954 2.3% 2.3% -
Intl 5,788 6,799 -14.9% -4.5% -10.4% 23,959 23,726 1.0% 11.9% -10.9%
WW 13,163	$ 14,217 -7.4% -2.5% -4.9% 52,563	$ 51,680 1.7% 6.7% -5.0%
See footnotes at end of schedule
% Change % Change

-- 18 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
MEDTECH SEGMENT (2,3,5) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 603	$ 483 24.9% 24.9% - 2,169	$ 1,836 18.2% 18.2% -
Intl 495 536 -7.6% 6.2% -13.8% 2,131 2,135 -0.2% 9.9% -10.1%
WW 1,098 1,019 7.8% 15.1% -7.3% 4,300 3,971 8.3% 13.7% -5.4%
ORTHOPAEDICS
US 1,385 1,305 6.1% 6.1% - 5,321 5,126 3.8% 3.8% -
Intl 763 851 -10.4% 0.8% -11.2% 3,267 3,462 -5.6% 3.4% -9.0%
WW 2,148 2,155 -0.4% 4.0% -4.4% 8,587 8,588 0.0% 3.7% -3.7%
HIPS
US 250 227 9.7% 9.7% - 943 878 7.3% 7.3% -
Intl 135 151 -10.4% 0.4% -10.8% 571 602 -5.1% 3.6% -8.7%
WW 385 378 1.7% 6.0% -4.3% 1,514 1,480 2.3% 5.8% -3.5%
KNEES
US 231 208 11.8% 11.8% - 851 787 8.2% 8.2% -
Intl 122 135 -9.5% 1.2% -10.7% 508 538 -5.7% 3.1% -8.8%
WW 354 342 3.4% 7.6% -4.2% 1,359 1,325 2.6% 6.1% -3.5%
TRAUMA
US 470 467 0.7% 0.7% - 1,882 1,819 3.5% 3.5% -
Intl 240 261 -7.9% 3.5% -11.4% 989 1,066 -7.2% 2.6% -9.8%
WW 710 728 -2.4% 1.7% -4.1% 2,871 2,885 -0.5% 3.1% -3.6%
SPINE, SPORTS & OTHER
US 434 403 7.5% 7.5% - 1,645 1,642 0.2% 0.2% -
Intl 265 304 -12.9% -1.5% -11.4% 1,198 1,256 -4.6% 4.3% -8.9%
WW 699 708 -1.3% 3.6% -4.9% 2,843 2,898 -1.9% 1.9% -3.8%
% Change % Change

-- 19 of 24 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency
SURGERY
US 1,000 986 1.5% 1.5% - 3,897 3,867 0.8% 0.8% -
Intl 1,383 1,527 -9.4% 1.4% -10.8% 5,793 5,945 -2.6% 5.7% -8.3%
WW 2,384 2,513 -5.1% 1.4% -6.5% 9,690 9,812 -1.2% 3.8% -5.0%
ADVANCED
US 456 457 -0.2% -0.2% - 1,784 1,761 1.3% 1.3% -
Intl 653 735 -11.1% -0.4% -10.7% 2,785 2,861 -2.6% 5.3% -7.9%
WW 1,109 1,192 -7.0% -0.3% -6.7% 4,569 4,622 -1.1% 3.8% -4.9%
GENERAL
US 544 528 3.1% 3.1% - 2,113 2,105 0.4% 0.4% -
Intl 731 793 -7.8% 3.0% -10.8% 3,008 3,085 -2.5% 6.2% -8.7%
WW 1,275 1,321 -3.5% 3.0% -6.5% 5,121 5,190 -1.3% 3.8% -5.1%
VISION
US 456 443 3.1% 3.1% - 1,990 1,857 7.2% 7.2% -
Intl 689 728 -5.4% 5.9% -11.3% 2,859 2,831 1.0% 11.1% -10.1%
WW 1,145 1,171 -2.2% 4.8% -7.0% 4,849 4,688 3.4% 9.5% -6.1%
CONTACT LENSES / OTHER
US 343 316 8.6% 8.6% - 1,522 1,398 8.9% 8.9% -
Intl 489 518 -5.6% 7.2% -12.8% 2,022 2,043 -1.0% 10.1% -11.1%
WW 831 833 -0.2% 7.7% -7.9% 3,543 3,440 3.0% 9.6% -6.6%
SURGICAL
US 113 126 -10.7% -10.7% - 468 459 2.0% 2.0% -
Intl 200 211 -5.0% 2.9% -7.9% 837 788 6.2% 13.7% -7.5%
WW 314 338 -7.1% -2.2% -4.9% 1,306 1,248 4.6% 9.4% -4.8%
TOTAL MEDTECH
US 3,445 3,216 7.1% 7.1% - 13,377 12,686 5.4% 5.4% -
Intl 3,331 3,643 -8.6% 2.9% -11.5% 14,050 14,374 -2.3% 6.9% -9.2%
WW 6,776	$ 6,859 -1.2% 4.9% -6.1% 27,427	$ 27,060 1.4% 6.2% -4.8%
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Previously referred to as Medical Devices
% Change % Change

-- 20 of 24 --

2022 2021 Total Operations Currency 2022 2021 Total Operations Currency
Pharmaceutical
U.S. 7,375	$ 7,418 (0.6) % (0.6) - 28,604	$ 27,954 2.3 % 2.3 -
International 5,788 6,799 (14.9) (4.5) (10.4) 23,959 23,726 1.0 11.9 (10.9)
Worldwide 13,163 14,217 (7.4) (2.5) (4.9) 52,563 51,680 1.7 6.7 (5.0)
COVID-19 Vaccine
U.S. 0 213 * * - 120 634 (81.1) (81.1) -
International 689 1,405 (50.9) (45.0) (5.9) 2,059 1,751 17.6 32.1 (14.5)
Worldwide 689 1,619 (57.4) (52.2) (5.2) 2,179 2,385 (8.6) 2.0 (10.6)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 7,375 7,205 2.4 2.4 - 28,484 27,320 4.3 4.3 -
International 5,099 5,394 (5.5) 6.0 (11.5) 21,900 21,975 (0.3) 10.3 (10.6)
Worldwide 12,474 12,599 (1.0) 3.9 (4.9) 50,384 49,295 2.2 6.9 (4.7)
Worldwide
U.S. 12,516 12,163 2.9 2.9 - 48,580 47,156 3.0 3.0 -
International 11,190 12,641 (11.5) (1.1) (10.4) 46,363 46,619 (0.6) 9.1 (9.7)
Worldwide 23,706 24,804 (4.4) 0.9 (5.3) 94,943 93,775 1.3 6.1 (4.8)
COVID-19 Vaccine
U.S. 0 213 * * - 120 634 (81.1) (81.1) -
International 689 1,405 (50.9) (45.0) (5.9) 2,059 1,751 17.6 32.1 (14.5)
Worldwide 689 1,619 (57.4) (52.2) (5.2) 2,179 2,385 (8.6) 2.0 (10.6)
Worldwide
U.S. 12,516 11,950 4.7 4.7 - 48,460 46,522 4.2 4.2 -
International 10,501 11,236 (6.5) 4.4 (10.9) 44,304 44,868 (1.3) 8.2 (9.5)
Worldwide excluding COVID-19 Vaccine 23,017	$ 23,186 (0.7) % 4.6 (5.3) 92,764	$ 91,390 1.5 % 6.2 (4.7)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FOURTH QUARTER TWELVE MONTHS
Percent Change Percent Change

-- 21 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 651 442 3,308 4,306 865 575 (153) (420) (470) (67) 4,201 4,836
% to Sales 17.3% 11.9% 25.1% 30.3% 12.8% 8.4% -0.6% -1.7% -2.0% -0.3% 17.7% 19.5%
Intangible asset amortization expense 84 100 717 761 260 260 - - - - 1,061 1,121
In-process research and development - - 173 - - - - - - - 173 -
Litigation related 72 122 61 (35) 129 187 - - - - 262 274
Loss/(gain) on securities - 1 23 (237) (17) 38 - - - - 6 (198)
Restructuring related 21 28 31 22 88 90 - - - - 140 140
Acquisition, integration and divestiture related - - (104) 5 300 21 - - - - 196 26
Medical Device Regulation - - - - 88 73 - - - - 88 73
COVID-19 Vaccine related costs - - 821 - - - - - - - 821 -
Consumer Health separation costs - - - - - - - - 470 67 470 67
Other - - - - - - - - - - - -
Adjusted Income Before Tax by Segment $ 828 693 5,030 4,822 1,713 1,244 (153) (420) - - 7,418 6,339
% to Sales 22.0% 18.6% 38.2% 33.9% 25.3% 18.1% -0.6% -1.7% 0.0% 0.0% 31.3% 25.6%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 1/24/2023
Q4 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 22 of 24 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 2,930 1,573 15,901 17,969 4,607 4,373 (624) (1,072) (1,089) (67) 21,725 22,776
% to Sales 19.6% 10.5% 30.3% 34.8% 16.8% 16.2% -0.7% -1.1% -1.1% -0.1% 22.9% 24.3%
Intangible asset amortization expense 361 414 2,911 3,258 1,033 1,025 - - - - 4,305 4,697
In-process research and development - - 783 - - 900 - - - - 783 900
Litigation related 150 1,603 104 640 612 85 - - - - 866 2,328
Loss/(gain) on securities - (18) 696 (486) (6) (29) - - - - 690 (533)
Restructuring related 91 119 63 76 309 278 - - - - 463 473
Acquisition, integration and divestiture related - - (104) (562) 300 84 - - - - 196 (478)
Medical Device Regulation - - - - 296 234 - - - - 296 234
COVID-19 Vaccine related costs - - 1,474 - - - - - - - 1,474 -
Consumer Health separation costs - - - - - - - 1,089 67 1,089 67
Other - - - - - - (7) - - - (7) -
Adjusted Income Before Tax by Segment $ 3,532 3,691 21,828 20,895 7,151 6,950 (631) (1,072) - - 31,880 30,464
% to Sales 23.6% 24.5% 41.5% 40.4% 26.1% 25.7% -0.7% -1.1% 0.0% 0.0% 33.6% 32.5%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
*Estimated as of 1/24/2023
Q4 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 23 of 24 --

Fourth Quarter Fourth Quarter
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 1, 2023
Non-GAAP
Cost of products sold 7,765	$ (1,060) (36) (33) (160) (4) - - - 6,472
Selling, marketing and admin expenses 6,512 (9) - (43) 6,460
Research and development expense 3,841 - (46) (114) - 3,681
Other (Income) / Expense 1,207 (1) (262) (20) (196) (6) (547) (423) - - (248)
In-process research and development 173 (173) -
Restructuring 84 (84) -
Provision for taxes on income 681 165 (36) 40 21 5 2 17 199 94 (35) 47 - 1,200
Net Earnings 3,520 896 298 133 119 191 4 71 622 376 35 (47) - 6,218
Fourth Quarter Fourth Quarter
Jan 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 2, 2022
Non-GAAP
Cost of products sold 7,955	$ (1,111) (21) (26) 6,797
Selling, marketing and admin expenses 7,154 (7) 7,147
Research and development expense 4,720 - (40) 4,680
Other (Income) / Expense 9 (10) (274) (36) (26) 198 - (67) - - (206)
In-process research and development - - -
Restructuring 83 (83) -
Provision for taxes on income 100 162 49 - 27 6 (89) 14 - 15 - 377 - 661
Net Earnings 4,736 959 225 - 113 20 (109) 59 - 52 - (377) - 5,678
Twelve Months Twelve Months
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 1, 2023
Non-GAAP
Cost of products sold 31,089	$ (4,292) (82) (109) (456) (4) 26,146
Selling, marketing and admin expenses 24,765 (28) (45) 24,692
Research and development expense 14,603 - (159) (304) 14,140
Other (Income) / Expense 1,871 (13) (866) (60) (196) (690) (714) (1,040) - 7 (1,701)
In-process research and development 783 (783) - - -
Restructuring 321 (321) -
Provision for taxes on income 3,784 667 (125) 178 81 5 166 56 360 206 (494) (40) (2) 4,842
Net Earnings 17,941 3,638 991 605 382 191 524 240 1,114 883 494 40 (5) 27,038
Twelve Months Twelve Months
Jan 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation Other
Jan 2, 2022
Non-GAAP
Cost of products sold 29,855	$ (4,661) (86) (85) 25,023
Selling, marketing and admin expenses 24,659 (24) 24,635
Research and development expense 14,714 - (125) 14,589
Other (Income) / Expense 489 (36) (2,328) (135) 478 533 - (67) - - (1,066)
In-process research and development 900 (900) -
Restructuring 252 (252) -
Provision for taxes on income 1,898 667 481 202 86 (98) (116) 44 - 15 - 1,090 - 4,269
Net Earnings 20,878 4,030 1,847 698 387 (380) (417) 190 - 52 - (1,090) - 26,195
(1) 2022 primarily includes costs related to the Abiomed acquisition. 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Year to Date
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
Consumer Health
separation tax
related costs
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related

-- 24 of 24 --